96 Chapter 4 REFERENCES 1. Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Compare. GBD Compare Data Visualization. 201AD [cited 2022 Jun 6]. Available from: http://www.healthdata.org/gbd/2019 2. Ergatoudes C, Thunström E, Rosengren A, Björck L, Bengtsson Boström K, Falk K, et al. Long-term secondary prevention of acute myocardial infarction (SEPAT)- guidelines adherence and outcome. BMC Cardiovasc Disord. 2016;16(1):1–8. 3. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): A prospective epidemiological survey. Lancet. 2011;378(9798):1231–43. 4. Naderi SH, Bestwick JP, Wald DS. Adherence to Drugs That Prevent Cardiovascular Disease : Meta-analysis on 376 ,162 Patients. AJM. 2012;125(9):882-887.e1. 5. Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373(9667):929– 40. 6. Maddox TM, Chan PS, Spertus JA, Tang F, Jones P, Ho PM, et al. Variations in coronary artery disease secondary prevention prescriptions among outpatient cardiology practices: Insights from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2014;63(6):539–46. 7. Avezum A, Oliveira GBF, Lanas F, Lopez-Jaramillo P, Diaz R, Miranda JJ, et al. Secondary CV Prevention in South America in a Community Setting: The PURE Study. Glob Heart. 2017;12(4):305– 8. Gaedke MA, Soares Dias da Costa J, Fernandes Manenti E, Henn RL, Vieira Paniz VM, Nunes MF, et al. Use of medicines recommended for secondary prevention of acute coronary syndrome. Rev Saúde Púbilca. 2015;49(88). 9. Birk MG, Carvalho Goulart A, Lotufo PA, Martins Benseñor I. Secondary prevention of coronary heart disease : a cross-sectional analysis on the Brazilian Longitudinal Study of Adult Health ( ELSA-Brasil ). Sao Paulo Med J. 2019;137(3):223–33. 10. Vianna CA, Gonzalez DA, Matijasevich A. Utilização de ácido acetilsalicílico ( AAS ) na prevenção de doenças cardiovasculares : um estudo de base populacional Aspirin use in cardiovascular disease prevention : a populationbased study. Cad Saúde Pública. 2012;28(6):1122–32. 11. Bruthans J, Mayer O, De Bacquer D, De Smedt D, Reiner Z, Kotseva K, et al. Educational level and risk profile and risk control in patients with coronary heart disease. Eur J Prev Cardiol. 2016;23(8):881–90. 12. Ohm J, Skoglund PH, Häbel H, Sundström J, Hambraeus K, Jernberg T, et al. Association of Socioeconomic Status with Risk Factor Target Achievements and Use of Secondary Prevention after Myocardial Infarction. JAMA Netw Open. 2021;4(3):1–14. 13. Kartschmit N, Beratarrechea A, Gutiérrez L, Cavallo AS, Rubinstein AL, Irazola V. Health care access and health-related quality of life among people with diabetes in the Southern Cone of Latin America—a cross-sectional analysis of data of the CESCAS I study. Qual Life Res 2021;30(4):1005–15. 14. Arce HE. Organización y financiamiento del sistema de salud en la Argentina. Med. 2012;72(5):414–8. 15. Belló M, Becerril-Montekio VM. Sistema de salud de Argentina. Salud Publica Mex. 2011;53(SUPPL. 2). 16. Aran D, Laca H. Sistema de salud de Uruguay. Salud Publica Mex. 2011;53(SUPPL. 2):265–74. 17. Becerril-Montekio V, de Dios Reyes J, Manuel A. Sistema de salud de Chile. Salud Publica Mex. 2011;53(SUPPL. 2). 18. Cetrángolo O. Financiamiento fragmentado, cobertura desigual y falta de equidad en el sistema de salud argentino. Rev Econ Política Buenos Aires. 2014;13(8):145–83. 19. Abreu MDE, Vensentini N, Mariani J, Gagliardi J, Tajer C. ARTÍCULO ORIGINAL Resultados Entre marzo 2006 y mayo 2016 se registró un total de Materiales y métodos. Medicina (B Aires). 2019;79:461–7. 20. Mendis S, Abegunde D, Yusuf S, Ebrahim S, Shaper G, Ghannem H. WHO study on Prevention of REcurrences of Myocardial Infarction and StrokE ( WHO-PREMISE ). Bull World Health Organ. 2005;83(11):820–31. 21. de Souza Groia Veloso RC, Cruzeiro M, Menezes Dias B, Moreira Reis AM. Profile of use and access to statins in patients with coronary arterial disease in an outpatient clinic of a teaching hospital. Curr Med Res Opin. 2020;36(9):1427–31. 22. Marin GH. The argentine health system: An analysis based on access to medicines. Cienc e Saude Coletiva. 2021;26(11):5453–62. 23. Smolderen K, Spertus J. Treatment Differences by Health Insurance Among Outpatients with Coronary Artery Disease: Insights from the NCDR. Bone. 2014;23(1):1–7. 24. Rubinstein AL, Irazola VE, Poggio R, Bazzano L, Calandrelli M, Zanetti FTL, et al. Detection and follow-up of cardiovascular disease and risk factors in the Southern Cone of Latin America: The CESCAS I study. BMJ Open. 2011;1(1):1–6. 25. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity
RkJQdWJsaXNoZXIy MTk4NDMw